These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9007217)

  • 1. HER-2/neu signal transduction in human breast and ovarian cancer.
    Reese DM; Slamon DJ
    Stem Cells; 1997; 15(1):1-8. PubMed ID: 9007217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the HER-2/neu oncogene in gynecologic cancers.
    Cirisano FD; Karlan BY
    J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic science of HER-2/neu: a review.
    Hung MC; Lau YK
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
    Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
    Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
    Menendez JA; Papadimitropoulou A; Vellon L; Lupu R
    Eur J Cancer; 2006 Oct; 42(15):2425-32. PubMed ID: 16406575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS; Fletcher JA
    Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer in the 21st century: neu opportunities and neu challenges.
    Schnitt SJ
    Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
    Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
    Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R; Sastre G; Serrano J; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
    Ross JS; Fletcher JA
    Am J Clin Pathol; 1999 Jul; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells.
    Pianetti S; Guo S; Kavanagh KT; Sonenshein GE
    Cancer Res; 2002 Feb; 62(3):652-5. PubMed ID: 11830514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas.
    Fan QB; Bian ML; Huang SZ; Lang JH; Ma J; Liu WS; Xu XY
    Chin Med J (Engl); 1994 Aug; 107(8):589-93. PubMed ID: 7805442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
    Hsu MC; Chang HC; Hung WC
    Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.